PSNL · Personalis, Inc.
$11.88
-0.10 (-0.83%)
At close · Jul 28
Market Cap
$1.24B
Shares
104.72M
Personalis, Inc. Earnings Call Transcripts
Every quarterly earnings call for Personalis, Inc. (PSNL) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼15.8%
$18.24M
−$27.55M
'22 Q2
22-08-03
▼33.3%
$14.86M
−$26.49M
'22 Q3
22-11-02
▼19.1%
$16.72M
−$31.07M
'22 Q4
23-02-23
▲23.9%
$18.86M
−$28.66M
'23 Q1
23-05-03
▼8.4%
$16.70M
−$23.95M
'23 Q2
23-08-08
▲22.8%
$18.25M
−$29.10M
'23 Q3
23-11-07
▲17.7%
$19.68M
−$26.58M
'23 Q4
24-02-28
▲3.5%
$19.52M
−$12.97M
'24 Q1
24-05-08
▲35.2%
$22.58M
−$12.80M
'24 Q2
24-08-07
▲40.9%
$25.71M
−$39.09M
'24 Q3
24-11-06
▲5.5%
$20.61M
−$15.75M
'25 Q1
25-05-06
▼23.8%
$17.20M
−$20.06M
'25 Q2
25-08-05
▼43.6%
$14.49M
−$21.65M
'25 Q3
25-11-04
▲3.2%
$17.34M
−$23.81M
'25 Q4
26-02-26
LATEST
▼24.9%
$15.47M
−$30.03M
'26 Q1
26-05-07
Earnings call
FY26 · Q2
2026-07-20
Personalis, Inc. Q2 FY2026 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Personalis, Inc. Q1 FY2026 Earnings Call
Confident tone
Clinical test volume growth and ordering physicians
Reimbursement and Medicare submissions
Biopharma MRD business and backlog
Revenue
$15.47M
▼ 24.9% YoY Diluted EPS
$-0.29
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Personalis, Inc. Q4 FY2025 Earnings Call
Confident tone
Medicare reimbursement coverage
MRD strategy and market opportunity
Clinical test volume growth
Revenue
$17.34M*
▲ 3.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Personalis, Inc. Q3 FY2025 Earnings Call
Positive tone
Medicare reimbursement and MolDX dossiers
Clinical volume growth and physician adoption
Clinical evidence and Phase III trial data
Revenue
$14.49M
▼ 43.6% YoY Diluted EPS
$-0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Personalis, Inc. Q2 FY2025 Earnings Call
Positive tone
Reimbursement / Medicare Coverage
Tempus Commercial Partnership
MRD Clinical Adoption (NeXT Personal)
Revenue
$17.20M
▼ 23.8% YoY Diluted EPS
$-0.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Personalis, Inc. Q1 FY2025 Earnings Call
Confident tone
MRD strategy and NeXT Personal adoption
Quarterly financial results and cash position
Reimbursement and Medicare submissions
Revenue
$20.61M
▲ 5.5% YoY Diluted EPS
$-0.18
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q3
2024-11-06
Personalis, Inc. Q3 FY2024 Earnings Call
Confident tone
NeXT Personal MRD product and clinical impact
Reimbursement pursuit
Tempus commercial partnership
Revenue
$25.71M
▲ 40.9% YoY Diluted EPS
$-0.64
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Personalis, Inc. Q2 FY2024 Earnings Call
Confident tone
MRD / NeXT Personal Test
Win-in-MRD Strategy and Pillars
Biopharma Growth
Revenue
$22.58M
▲ 35.2% YoY Diluted EPS
$-0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Personalis, Inc. Q1 FY2024 Earnings Call
Confident tone
MRD strategy and NeXT Personal launch
NeXT Dx / Tempus relationship
Natera collaboration
Revenue
$19.52M
▲ 3.5% YoY Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Personalis, Inc. Q4 FY2023 Earnings Call
Confident tone
Biopharma and enterprise partnerships
Win-in-MRD strategy and NeXT Personal
Clinical evidence and reimbursement
Revenue
$19.68M*
▲ 17.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Personalis, Inc. Q3 FY2023 Earnings Call
Revenue
$18.25M
▲ 22.8% YoY Diluted EPS
$-0.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Personalis, Inc. Q2 FY2023 Earnings Call
Revenue
$16.70M
▼ 8.4% YoY Diluted EPS
$-0.50
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Personalis, Inc. Q1 FY2023 Earnings Call
Revenue
$18.86M
▲ 23.9% YoY Diluted EPS
$-0.61
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Personalis, Inc. Q4 FY2022 Earnings Call
Revenue
$16.72M*
▼ 19.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Personalis, Inc. Q3 FY2022 Earnings Call
Revenue
$14.86M
▼ 33.3% YoY Diluted EPS
$-0.58
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Personalis, Inc. Q2 FY2022 Earnings Call
Revenue
$18.24M
▼ 15.8% YoY Diluted EPS
$-0.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Personalis, Inc. Q1 FY2022 Earnings Call
Revenue
$15.23M
▼ 27.1% YoY Diluted EPS
$-0.63
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Personalis, Inc. Q4 FY2021 Earnings Call
Revenue
$20.68M*
▲ 2.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Personalis, Inc. Q3 FY2021 Earnings Call
Revenue
$22.26M
▲ 12.3% YoY Diluted EPS
$-0.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Personalis, Inc. Q2 FY2021 Earnings Call
Revenue
$21.67M
▲ 11.2% YoY Diluted EPS
$-0.34
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Personalis, Inc. Q1 FY2021 Earnings Call
Revenue
$20.88M
▲ 9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Personalis, Inc. Q4 FY2020 Earnings Call
Revenue
$20.18M*
▲ 11.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Personalis, Inc. Q3 FY2020 Earnings Call
Revenue
$19.82M
▲ 15.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Personalis, Inc. Q2 FY2020 Earnings Call
Revenue
$19.50M
▲ 23.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Personalis, Inc. Q1 FY2020 Earnings Call
Revenue
$19.16M
▲ 36.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-25
Personalis, Inc. Q4 FY2019 Earnings Call
Revenue
$18.15M
▲ 38% YoY Gross margin
36.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–26 of 26 earnings calls
Key facts
CIK
1527753
CUSIP
71535D106
13F (30d)
14 filings
14 filers
Visit website
Investor relations